|SBBP -- USA Stock|| |
USD 4.25 0.25 6.25%
We currently do not have informatin regarding Per MD. This executive tanure with Strongbridge Biopharma plc is not currenlty determined.
The company has return on total asset (ROA)
of (29.46) %
which means that it has lost $29.46 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (914.29) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 77.57 M in liabilities with Debt to Equity (D/E) ratio of 875.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Strongbridge Biopharma plc has Current Ratio of 6.33 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania. Strongbridge Biopharma operates under Biotechnology classification in USA and traded on NASDAQ. It employs 66 people.Strongbridge Biopharma plc (SBBP) is traded on NASDAQ in USA. It is located in 900 Northbrook Drive and employs 66 people.
Strongbridge Biopharma Leadership Team
|Matthew Pauls, CEO and President and Director|
|Brian Davis, CFO|
|Richard Kollender, Director|
|Robert Lutz, Chief Bus. Officer|
|Garheng Kong, Director|
|John Johnson, Chairman of the Board|
|Marten Steen, Director|
|Stephen Long, Chief Legal Officer|
|Ruth MD, Chief Medical Officer|
|Ruth ThieroffEkerdt, Chief Medical Officer|
|Hilde Steineger, Director|
|Per MD, Founder and Sr. Clinical Advisor|
Stock Performance Indicators